Horizon Stock Performance

HZNP
 Stock
  

USD 104.18  3.30  3.27%   

On a scale of 0 to 100, Horizon Pharma holds a performance score of 16. The company retains a Market Volatility (i.e., Beta) of 1.1337, which attests to a somewhat significant risk relative to the market. Let's try to break down what Horizon's beta means in this case. Horizon Pharma returns are very sensitive to returns on the market. As the market goes up or down, Horizon Pharma is expected to follow. Although it is vital to follow Horizon Pharma PLC current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Horizon Pharma PLC, which you can use to evaluate the performance of the firm. Please utilizes Horizon Pharma value at risk, as well as the relationship between the skewness and day median price to make a quick decision on whether Horizon Pharma PLC current trending patterns will revert.
  
Horizon Performance
16 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Horizon Pharma PLC are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Horizon Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Horizon Price Channel

Begin Period Cash Flow2083479000.00
Total Cashflows From Investing Activities-2994111000.00

Horizon Pharma Relative Risk vs. Return Landscape

If you would invest  5,963  in Horizon Pharma PLC on September 3, 2022 and sell it today you would earn a total of  4,125  from holding Horizon Pharma PLC or generate 69.18% return on investment over 90 days. Horizon Pharma PLC is currently generating 0.9321% in daily expected returns and assumes 4.2747% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Horizon, and 82% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Horizon Pharma is expected to generate 2.82 times more return on investment than the market. However, the company is 2.82 times more volatile than its market benchmark. It trades about 0.22 of its potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.09 per unit of risk.

Horizon Pharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Horizon Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Horizon Pharma PLC, and traders can use it to determine the average amount a Horizon Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.2181

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsHZNP
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 4.27
  actual daily
 
 37 %
of total potential
 
3737
Expected Return
 0.93
  actual daily
 
 18 %
of total potential
 
1818
Risk-Adjusted Return
 0.22
  actual daily
 
 16 %
of total potential
 
1616
Based on monthly moving average Horizon Pharma is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Horizon Pharma by adding it to a well-diversified portfolio.

About Horizon Pharma Performance

To evaluate Horizon Pharma PLC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Horizon Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Horizon Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Horizon Pharma PLC market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Horizon's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-10.6 M-10.9 M
Return on Average Assets 0.06  0.07 
Return on Average Equity 0.12  0.13 
Return on Invested Capital 0.11  0.12 
Return on Sales 0.17  0.18 

Things to note about Horizon Pharma PLC

Checking the ongoing alerts about Horizon Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Horizon Pharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Horizon Pharma Alerts

Equity Alerts and Improvement Suggestions

Horizon Pharma PLC appears to be risky and price may revert if volatility continues
Over 97.0% of the company shares are owned by institutional investors
Latest headline from Macroaxis: Is Pfizer more volatile than Horizon Therapeutics
Please check Risk vs Return Analysis. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for analysis

When running Horizon Pharma PLC price analysis, check to measure Horizon Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Horizon Pharma is operating at the current time. Most of Horizon Pharma's value examination focuses on studying past and present price action to predict the probability of Horizon Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Horizon Pharma's price. Additionally, you may evaluate how the addition of Horizon Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Is Horizon Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Horizon Pharma. If investors know Horizon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Horizon Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.58) 
Market Capitalization
22.7 B
Quarterly Revenue Growth YOY
(0.11) 
Return On Assets
0.0557
Return On Equity
0.12
The market value of Horizon Pharma PLC is measured differently than its book value, which is the value of Horizon that is recorded on the company's balance sheet. Investors also form their own opinion of Horizon Pharma's value that differs from its market value or its book value, called intrinsic value, which is Horizon Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Horizon Pharma's market value can be influenced by many factors that don't directly affect Horizon Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Horizon Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Horizon Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Horizon Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.